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The Fgf4 gene encodes an important signaling molecule which is expressed in specific developmental stages, including the
inner cell mass of the blastocyst, the myotomes, and the limb bud apical ectodermal ridge (AER). Using a transgenic
approach, we previously identified overlapping but distinct enhancer elements in the Fgf4 3* untranslated region necessary
and sufficient for myotome and AER expression. Here we have investigated the hypothesis that Fgf4 is a target of myogenic
bHLH factors. We show by mutational analysis that a conserved E box located in the Fgf4 myotome enhancer is required
for Fgf4-lacZ expression in the myotomes. A DNA probe containing the E box binds MYF5, MYOD, and bHLH-like
activities from nuclear extracts of differentiating C2-7 myoblast cells, and both MYF5 and MYOD can activate gene
expression of reporter plasmids containing the E-box element. Analyses of Myf5 and MyoD knockout mice harboring
Fgf4-lacZ transgenes show that Myf5 is required for Fgf4 expression in the myotomes, while MyoD is not, but MyoD can
ustain Fgf4 expression in the ventral myotomes in the absence of Myf5. Sonic hedgehog (Shh) signaling has been shown to
ave an essential inductive function in the expression of Myf5 and MyoD in the epaxial myotomes, but not in the hypaxial
myotomes. We show here that expression of an Fgf4-lacZ transgene in Shh2/2 embryos is suppressed not only in the
epaxial but also in the hypaxial myotomes, while it is maintained in the AER. This suggests that Shh mediates Fgf4
ctivation in the myotomes through mechanisms independent of its role in the activation of myogenic factors. Thus, a
ascade of events, involving Shh and bHLH factors, is responsible for activating Fgf4 expression in the myotomes in a
patial- and temporal-specific manner. © 2000 Academic Presst
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Embryonic development requires a complex program of
events coordinated by extracellular signaling molecules
that activate or repress transcription of specific gene sub-
sets and thus influence the proliferative state or identity of
the target cells. The expression of these signaling molecules
has to be rigorously and specifically regulated, and the
identification of the regulatory mechanisms that control
expression of these molecules is fundamental to an under-
standing of the process of development.
Members of the fibroblast growth factor (FGF) family
have been shown to influence a wide range of developmen-
1 To whom correspondence should be addressed. Fax: (212) 263-
8714.
392al events. Experiments using gene knockout and trans-
enic technology, as well as evidence from human genetics,
ave revealed that FGF signaling plays a major role in many
spects of development, including postimplantation mouse
evelopment, gastrulation, midbrain formation, myogen-
sis, growth and patterning of the limb, and bone morpho-
enesis. An important role in development has been dem-
nstrated for FGF4. This growth factor is essential for
ostimplantation mouse development, since embryos ho-
ozygously null for the Fgf4 gene undergo uterine implan-
tation but do not develop substantially thereafter, and is
also likely to be involved in limb growth and patterning
(Basilico and Moscatelli, 1992; Goldfarb, 1996).
The pattern of expression of Fgf4 is highly specific, being
both spatially and temporally restricted to very discrete
embryonic tissues (Niswander and Martin, 1992; Drucker
0012-1606/00 $35.00
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393Fgf4 Regulation by Myogenic bHLH Factors and Shhand Goldfarb, 1993). Fgf4 RNA is first detected in the inner
cell mass (ICM) of the blastocyst at embryonic day 4.5 (E4.5)
and then in the primitive streak (E7), the branchial arches
and somitic myotomes (E9.5–13.5), and the apical ectoder-
mal ridge (AER) of the limb bud (E10.5–11.5). Although the
pattern of expression suggests a role for Fgf4 during myo-
genesis, the early embryonic lethality of the Fgf4 null
mbryos has precluded the study of its role in muscle
evelopment. Fgf4 RNA is first detected in the myotomes
t E9.5 just prior to or at approximately the same time as
gf6. By E14.5, when Fgf6 RNA is widely expressed in
keletal muscle, Fgf4 RNA is no longer detected in any
uscle cells (Niswander and Martin, 1992; Han and Martin,
993). Fgf5 is also known to be expressed in the myotome,
ith transcripts first becoming detectable at E10.5 (Haub
nd Goldfarb, 1991). The profile of Fgf4 gene expression
mong skeletal muscle groups is overlapping, but distinct
rom, that of Fgf5, thereby revealing myoblast heterogenic-
ty and suggesting distinct roles for multiple FGFs in
uscle development (Drucker and Goldfarb, 1993).
Using a transgenic approach we previously defined dis-
inct regulatory elements in the 39 untranslated region (39
TR) of the Fgf4 gene capable of driving lacZ gene expres-
ion in a manner which faithfully recapitulates the expres-
ion of the endogenous gene in the mouse blastocyst,
yotomes, and developing limb (Fraidenraich et al., 1998).
hile the cis and trans-acting elements governing Fgf4
expression in the blastocyst have been previously well
defined in our laboratory (Curatola and Basilico, 1990;
Dailey et al., 1994; Yuan et al., 1995), the DNA elements
controlling expression in the myotomes and AER appear to
be overlapping but distinct. Within the myotomal/AER
core enhancer element there are two E boxes (E-box 1 and
E-box 2) and mutation of both E boxes abolished transgene
expression in the myotomes, but not in the AER (Fraiden-
raich et al., 1998).
E boxes (CANNTG) represent the consensus binding site
for a large group of transcriptional regulators, the bHLH
proteins, that includes the myogenic factors MYOD, MYF5,
myogenin, and MRF4 (Molkentin and Olson, 1996; Cossu et
al., 1996b). Myogenic bHLH factors are expressed in over-
lapping but distinct patterns during muscle development,
and a number of genetic experiments show that their
activity is essential for establishing myoblast identity and
muscle differentiation. Particularly MyoD and Myf5 are
thought to play a very early but partially redundant role in
muscle development, since deletion of both of these genes
results in complete suppression of muscle formation and in
the absence of skeletal myoblasts, while the ablation of
either Myf5 or MyoD alone does not significantly affect
muscle development (Rudnicki et al., 1992, 1993; Braun et
al., 1992).
Although MyoD and Myf5 proteins presumably regulate
the expression of genes that collaborate to establish or
maintain myogenic commitment, no direct target gene
encoding for a growth factor in muscle progenitors has been
yet identified. Grass et al. (1996) found that the expression
Copyright © 2000 by Academic Press. All rightof members of the FGF family was absent or delayed in the
somites of Myf5 mutant embryos. In this report we inves-
tigate the hypothesis that Fgf4 is a target of myogenic
bHLHs. We show by mutational analysis that the conserved
E-box 2 but not E-box 1 is required for Fgf4-lacZ expression
in the myotomes and cannot be compensated for by other E
boxes situated in the 39 UTR. Accordingly, an E-box 2 DNA
probe binds efficiently MYF5, MYOD, and bHLH-like ac-
tivities from nuclear extracts of differentiating C2-7 myo-
blast cells, and both MYF5 and MYOD can stimulate gene
expression of reporter plasmids containing E-box 2 se-
quences. To ascertain which of the myogenic bHLH factors
influences Fgf4 expression in the myotomes we crossed
Myf5 and MyoD knockout mice with Fgf4-lacZ transgenic
mouse lines. The results of these analyses show that Myf5
is required for Fgf4 expression in the myotomes, but that
MyoD can also contribute to the activity of the Fgf4
myotome enhancer in the absence of Myf5. Finally, we
present evidence indicating that Fgf4 gene expression in the
myotomes is also dependent on Sonic hedgehog (Shh) sig-
naling. Taken together, these data represent the first de-
scription of the molecular mechanisms that control the
epaxial lineage expression of a myotome-specific gene.
MATERIAL AND METHODS
Plasmid DNAs
To make the constructs for the transient transgenesis experi-
ments an Fgf4-lacZ plasmid containing the Fgf4 murine promoter,
he Fgf4 splicing sequences, and bacterial b-galactosidase coding
sequences, and the SV40 poly(A) site was used (Fraidenraich et al.,
1998). In the murine genomic sequences, nucleotide 1 corresponds
to an EcoRI site located 3823 and 5257 nt upstream of the ATG
initiation codon and TGA termination codon of the murine Fgf4
gene, respectively. To make constructs 2 and 3, a 337-bp fragment
(nt 6260–6597) from the Fgf4 39 UTR was inserted 39 of the SV40
poly(A) site. Construct 2 carries a mutation in E-box 1 and
construct 3 in E-box 2 (G to A substitutions in nt 6267 and 6362,
respectively). To make construct 4 a 1744-bp fragment (nt 5705–
7449) from the Fgf4 39 UTR that carries a mutation in E-box 2 was
inserted. Mutations were performed by PCR (Fraidenraich et al.,
1998). To make the Fgf4-CAT constructs an Fgf-CAT plasmid
derived from the pCAT3-Basic Vector (Promega) and containing the
minimal Fgf4 murine promoter (nt 264 to nt 1150) was used
(Ambrosetti et al., 2000). To generate constructs 3a1 and 3a2, the
178- (nt 6251–6429) or 171-bp (nt 6429–6600) fragment, respec-
tively, was inserted 59 of the Fgf4 promoter. To make constructs
8X(E-box 1) and 8X(E-box 2), oligonucleotides consisting of two
repeats of 20 nt encompassing the E-box 1 and E-box 2 motifs (nt
6255–6274 and nt 6349–6368, respectively) were multimerized by
self-ligation and inserted 59 of the Fgf4 promoter.
Transient Transgenesis Experiments
Fgf4-lacZ constructs were linearized using the appropriate re-
striction enzymes, agarose gel-purified, electroeluted, concentrated
with Elutip-D minicolumns (S&S), and resuspended at a concen-
tration of 100–300 mg/ml. Standard microinjection of DNA into
s of reproduction in any form reserved.
Cf
a
m
e
i
S
M
2
M
p
a
1
e
e
e
g
g
e
(
d
d
t
a
s
a
t
F
A
h
b
e
r
i
i
e
c
h
M
e
394 Fraidenraich et al.the pronucleus of fertilized eggs was achieved at the NYU Trans-
genic Mouse Facility. Swiss Webster mice were used.
Cell Culture, Transfections, and CAT Assay
HeLa, NIH-3T3, and C2-7 myoblast cells were grown in DMEM
supplemented with 10% calf serum (CS). To induce C2-7 cell
differentiation, the cells were grown in DMEM plus 1% horse
serum (HS). CaPO4 transfections were performed as described in
uratola and Basilico (1990).
Nuclear Extracts, Whole-Cell Extracts, and EMSA
For nuclear extracts (NE), pelleted C2-7 myoblast cells (grown in
10% CS or 1% HS) were resuspended in NE buffer (0.1 mM EDTA
and EGTA, 1 mM DTT, protease inhibitors, pH 7.9) containing 10
mM KCl and 0.6% NP-40. Nuclei were pelleted and resuspended in
NE buffer containing 400 mM NaCl. For whole-cell extracts (WCE)
cells were harvested, resuspended in 20 mM Tris–HCl, pH 7.9, 450
mM KCl, 20% glycerol, 1 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT,
0.02% NP-40 and freeze–thawed. Oligonucleotides were labeled
with T4 polynucleotide kinase and [g-32P]ATP. EMSAs were per-
ormed as in Dailey et al. (1994) using 6 ml of NE or 2 ml of WCE
and, where indicated, 10-, 100-, or 200-fold molar excess of com-
petitor oligonucleotide or 2 or 4 ml of a monoclonal antibody
reactive with MYOD.
Interbreeding, Collection of Embryos, and X-gal
Staining
Myf51/2 (Rudnicki et al., 1992), MyoD2/2 (Braun et al., 1992),
nd Shh1/2 (Chiang et al., 1996) mice were first bred with two
ouse lines carrying transgenes that encompass the myotomal
nhancer element Hom3a (Fig. 3). The progeny were subsequently
nterbred to obtain Myf52/2:Fgf4-lacZ, MyoD2/2:Fgf4-lacZ, and
hh2/2:Fgf4-lacZ embryos. Additionally, Myf51/2 and
yoD1/2 transgenics were intercrossed to produce mice Myf51/
:MyoD1/2:Fgf4-lacZ. After another round Myf52/2:MyoD2/2,
yf52/2:MyoD1/2, and Myf51/2:MyoD2/2 transgenics were
roduced. Embryos were collected between E10.5 and E13.5, fixed,
nd stained with X-gal as described previously (Fraidenraich et al.,
998). Genomic DNA was isolated from mouse tails or from
mbryonic yolk sacs (Fraidenraich et al., 1998), and the mice or
mbryos were genotyped by Southern blot analysis. At least three
mbryos of each genotype containing one allele of the lacZ trans-
ene were derived and characterized. Whole embryos were photo-
raphed using a Leica stereomicroscope.
Immunohistochemistry
X-gal-stained embryos were fixed in 4% paraformaldehyde and
sectioned transversely using a Zeiss cryostat or a Zeiss microtome.
Immunostaining was performed using the biotin/avidin system
(Vectastain), according to the manufacturer’s instructions (Vector
Laboratories, Inc.) using the primary antibodies mAb 5.8A against
mouse MYOD (kindly provided by P. Loughton), mAb D33 against
mouse desmin (DAKO, Denmark), antibody 5C-302 against Myf5
(Santa Cruz), mAb F5D against myogenin (developed by W. E.
Wright, Developmental Studies Hybridoma Bank), and mAb MF20
against myosin heavy chain (MHC) (Bader et al., 1982).
Copyright © 2000 by Academic Press. All rightWhole-Mount in Situ Hybridization
Whole embryos were dissected at E11.5 and processed as de-
scribed by Henrique et al. (1995). For detection of Fgf4 mRNA, two
digoxigenin-labeled antisense probes corresponding to the Fgf4 first
xon or homology region 2 of the Fgf4 39 UTR were used together
Fraidenraich et al., 1998). For detection of MyoD mRNA, a
igoxigenin-labeled antisense probe was transcribed from a PCR-
erived DNA template corresponding to the carboxyl terminus of
he MyoD coding sequence (nt 761–1061) using T3 RNA polymer-
se. Whole embryos were photographed using a Leica stereomicro-
cope.
RESULTS
A Conserved E Box Situated in the 3* UTR of the
Fgf4 Gene Is Required for Fgf4-lacZ Expression in
the Myotomes
We previously identified a 337-bp myotomal enhancer
element in a conserved region within the 39 UTR of the
murine Fgf4 gene (homology region 3a, Hom3a) by its
bility to direct expression of a Fgf4-lacZ transgene to the
runk and tail myotomes (Fraidenraich et al., 1998). The
gf4 promoter sequences have no activity in isolation. The
ER enhancer elements overlap with the myotomal en-
ancer sequences but are distinct, since mutation of two E
oxes present in the Hom3a region abolishes transgene
xpression in the myotomes but not in the AER (Fraiden-
aich et al., 1998). These observations prompted us to
nvestigate if both E boxes are required for transgene activ-
ty, or only one E box is important, and whether these
lements are redundant.
In order to answer these questions, we created three new
onstructs and produced transgenic embryos, which were
arvested at E11.5 and subjected to X-gal staining (Fig. 1).
utation of E-box 1 (construct 2) did not alter the pattern of
xpression of the Fgf4 transgene (Fig. 1B), compared to the
pattern of the transgene driven by the intact Hom3a (data
not shown and Fraidenraich et al., 1998). Mutation in E-box
2 (construct 3), however, led to a complete loss of transgene
expression in the myotomes (Fig. 1C). The expression of a
construct bearing a mutation in E-box 2 in the context of
most of the 39 UTR sequences that contain six additional E
boxes (including E-box 1) was also examined (construct 4).
There was no detectable expression of this transgene in the
myotomes (Fig. 1D), indicating that the absence of E-box 2
function cannot be compensated for by other E boxes of the
39 UTR. Ectopic areas of expression were observed, such as
in the dorsal root ganglia (Fig. 1D). We sectioned these
embryos and confirmed the absence of staining in the
myotomes. Expression in the AER was weak but detectable
when constructs 2 and 3 were used and stronger in the case
of construct 4 (data not shown).
To confirm that the pattern observed in the myotomes
with the construct 1 or 2 transgenics is similar to that of the
endogenous Fgf4 transcripts, we performed whole-mount in
situ hybridization analysis on E11.5 embryos with DIG
s of reproduction in any form reserved.
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Copyright © 2000 by Academic Press. All rightprobes for Fgf4 and MyoD. The pattern of expression of Fgf4
RNA was very similar to the transgene pattern (Fig. 1E,
ompare to Fig. 1B). Interestingly, both Fgf4-lacZ and Fgf4
mRNA were observed in a subset of the myotomes. MyoD
is known to be expressed throughout the myotome at E10.5
(Cossu et al., 1996a). The expression of MyoD mRNA was
dorsoventrally more extended than that observed for Fgf4
(Fig. 1F, compare to Figs. 1E and 1B). This is more clearly
seen in Fig. 1G, which shows a section of a transgenic
embryo (E11.5) stained with X-gal and immunostained with
anti-MYOD antibodies. While MYOD-positive cells demar-
cate the entire myotome, including the dorsal and ventral
domains, b-gal-positive cells are observed only in a central
area with respect to the dorsoventral axis, predominantly in
the epaxial domain. The b-gal-positive domain contacts the
clerotomal layer, but not the dermatome. We also deter-
ined the expression of Myf5 in the myotomes and com-
ared it with that of Fgf4-lacZ (Fig. 1H). Also in this case,
yf5 expression was more extended than that of lacZ,
hich was confined to the central area of Myf5 expression.
ur observation that Fgf4 (both Fgf4-lacZ and Fgf4 mRNA)
is expressed in a subset of the myotomes is in agreement
with previous observations by Drucker and Goldfarb (1993),
who also reported that Fgf4 mRNA detection in the myo-
tomes is confined to a centrally located area.
The E-box 2 Element but Not E-box 1 Binds MYF5
and MYOD
The myogenic bHLH transcription factor family can be
divided into two functional groups. MYF5 and MYOD
appear to be required for the determination of skeletal
myoblasts. Myogenin and MRF4 act later in the program,
and their role is likely to be that of differentiation factors
(Rudnicki et al., 1993; Braun et al., 1994; Rawls et al., 1995;
Megeney and Rudnicki, 1995). The temporal pattern of
expression of Fgf4 in the myotomes and its apparent re-
quirement for the E-box 2 element suggested that either
MYF5 or MYOD might be involved in activation of Fgf4
transient assays with consistent results: Vertical bars, intact E
boxes; x, mutant E box. Hom 2, 3a, and 3b, 39 UTR homology
regions 2 (black rectangle), 3a (gray rectangles), and 3b (hatched
rectangles). (B) X-gal staining of an E11.5 embryo carrying construct
2. (C) X-gal staining of an E11.5 embryo carrying construct 3. (D)
X-gal staining of an E11.5 embryo carrying construct 4. Ectopic
staining is detected in the dorsal root ganglia (arrow). (E and F)
Whole-mount in situ hybridization of wild-type E11.5 embryos
using antisense DIG probes for Fgf4 (E) and MyoD (F) mRNAs as
described under Material and Methods. (G and H) An E11.5
Fgf4-lacZ transgenic embryo was X-gal stained, sectioned at the
interlimb level, and immunostained with anti-MYOD (G) or anti-
MYF5 (H) antibodies as described under Material and Methods. d,
dorsal; v, ventral; scl, sclerotome; derm, dermatome; nt, neuralFIG. 1. E-box 2 but not E-box 1 is required for Fgf4-lacZ expres-
ion in the myotomes. (A) Schematic representation of the en-
ancer elements used to create Fgf4-lacZ transgenic embryos (see
aterial and Methods for details). Fragment 2 is identical to
ragment 1 (Hom3a; Fraidenraich et al., 1998) but carries a mutant
-box 1; fragment 3 carries a mutant E-box 2; fragment 4 contains
ost of the 39 UTR sequences including Hom2, intervening
equences, Hom3a carrying a mutant E-box 2, Hom3b, and flanking
equences. For coordinates see Material and Methods. At least fivetube.
s of reproduction in any form reserved.
396 Fraidenraich et al.gene expression in the myotomes. To test whether E-box 2
binds MYF5 and MYOD and to study the basis of the
functional specificity of the two E boxes, we performed
EMSAs using whole-cell extracts derived from HeLa cells
transfected with Myf5 or MyoD expression plasmids.
FIG. 2. The Fgf4 E-box 2 site binds MYF5, MYOD, and nuclear c
Electrophoretic mobility shift of an Fgf4 E-box 2 probe (see sequence
1–3; B, lanes 1–4; C, lanes 1–3; see also E, lane 10), MyoD (A, lan
expression plasmids or untransfected (A, lanes 7–9; C, lane 7). 26-m
E-box 2 (A, lanes 2, 5, and 8; C, lanes 2 and 5; and D, lanes 2–4); CA
3, 6, and 9); CACCTG, DNA from the MCK enhancer (B, lanes 2 an
sequences (B, lanes 3 and 7); CAGCTA, Fgf4 E-box 2 with a G to A
bottom). (E and F) Electrophoretic mobility shift of Fgf4 E-box 2 pr
HS for 0 (E, lanes 1–3), 48 (E, lanes 4–6), and 90 h (E, lanes 7–9, an
8) and CAGGTA (lanes 3, 6, and 9). The formation of complexes a, b
the extracts derived from differentiating C2-7 myoblasts (lanes 1–
Material and Methods.Probe E-box 2, consisting of E-box 2 plus flanking se-
Copyright © 2000 by Academic Press. All rightquences (Fgf4 E-box 2, Fig. 2) was incubated with extracts
derived from HeLa cells transfected with Myf5 and MyoD
expression plasmids. Two bands representing the formation
of complexes between E-box 2 and MYOD and one band
representing the formation of a complex between E-box 2
xtracts derived from differentiating C27-myoblasts. (A through D)
ottom) in a HeLa whole-cell extract transfected with Myf5 (A, lanes
–6; B, lanes 5–8; C, lanes 4–6; D, lanes 1–7; see also E, lane 11)
NAs were used to comp ete the binding of the probe. E-box 2, Fgf4
A, Fgf4 E-box 2 with the second half of the E box mutated (A, lanes
nd D, lanes 5–7); CACATG, E-box 1 element plus E-box 2 flanking
stitution (B, lanes 4 and 8); E-box 1, Fgf4 E-box 1 (see sequence at
n a nuclear cell extract derived from C2-7 myoblasts grown in 1%
anes 1–3). (E) DNAs used for competition: E-box 2 (lanes 2, 5, and
, and e is detected. (F) Anti-MYOD antibodies were incubated with
from MyoD-transfected HeLa cells (lanes 4–6) as described underell e
at b
es 4
er D
GGT
d 6, a
sub
obe i
d F, l
, c, d
3) orand MYF5 are detected in transfected but not in untrans-
s of reproduction in any form reserved.
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397Fgf4 Regulation by Myogenic bHLH Factors and Shhfected cells extracts. Binding was competed when the
incubation was performed in the presence of excess of cold
E-box 2, but not in the presence of excess of mutant E-box
2 in which we substituted the second half of the E-box 2
element (CAGGTA) (Fig. 2A). Probe E-box 1, consisting of
E-box 1 and flanking sequences (Fgf4 E-box 1, Fig. 2), did not
produce any specific complexes using these extracts (data
not shown).
The binding of E-box 2 to MYF5 and MYOD was further
characterized using four additional competitors. We used a
sequence from the muscle creatine kinase enhancer con-
taining a functional E box (CACCTG; Jaynes et al., 1988)
and another DNA corresponding to E-box 2 with the two
central nucleotides substituted (CACATG). This E box is
identical to the E-box 1 element but the flanking sequences
correspond to E-box 2. The third DNA oligomer was an-
other mutant E-box 2, in which we substituted the sixth
nucleotide of E-box 2, disrupting again the E box
(CAGCTA). The G to A substitution had been used to
create mutant E boxes in the transgenic analyses of Fig. 1
and previously (Fraidenraich et al., 1998). The fourth DNA
oligomer was E-box 1 and flanking sequences. The binding
of MYOD and MYF5 to E-box 2 was competed with
CACCTG and E-box 2 with similar affinities, but not with
CACATG, CAGCTA, or E-box 1 (Figs. 2B–2D and data not
shown). Thus the E-box 2 element is capable of binding
myogenic bHLH factors, while the E-box 1 is not, in
agreement with the hypothesis that the requirement for
E-box 2 shown in vivo reflects the binding and activation by
yogenic factors.
Expression of Fgf4-lacZ in the Myotomes of Myf5-
but Not of MyoD-Deficient Embryos Is Severely
Impaired
The requirement for E-box 2 and its binding to MYF5 and
MYOD led us to investigate whether these factors play a
role in controlling Fgf4 gene expression. To this end, we
crossed two Fgf4-lacZ transgenic mouse lines with mice
eficient for Myf5 or MyoD to obtain transgenic, Myf5 or
yoD null embryos. Both transgenes express lacZ under
he control of most of the sequences of the 39 UTR (Fraid-
nraich et al., 1998), which include the intact Hom3a
yotomal enhancer element (Fig. 3). We tested therefore
he ability of Fgf4 Hom3a to drive lacZ expression in the
yotomes in the context of MyoD or Myf5 null embryos.
Embryos were harvested between E10.5 and E13.5 and
ubjected to X-gal staining. An identical pattern of staining
as observed in the trunk and tail myotomes and derivative
uscles including the intercostal and deep back muscles
ith both Fgf4-lacZ transgenic lines analyzed in wild-type
mbryos. The absence of MyoD did not affect the expres-
ion of the Fgf4 transgene at any of the developmental
tages examined (Figs. 3C, 3F, 3I, and 3L, compare with
ild-type embryos in 3A, 3D, 3G, and 3J). In contrast, the
xpression of the Fgf4 transgene was severely compromised
n the Myf5 null embryos (Figs. 3B, 3E, 3H, and 3K). At l
Copyright © 2000 by Academic Press. All right10.5–E11.0, X-gal staining of the myotomes was absent in
he Myf5 KO embryos, although lacZ expression was acti-
ated in the limb-bud AERs and was indistinguishable from
hat of the wild-type embryos (Fig. 3B vs Fig. 3A). At E11.5
nd E12.5 in the Myf5 KO embryos, only weak positive
reas were detected in the myotomes (Figs. 3E and 3H) and
hey were localized to the ventral portion of the myotomes
f the interlimb somites and to small centers in the dorsal
yotomes (see arrows). At E13.5 the muscles derived from
he trunk and tail myotomes presented little or no X-gal
taining, with only a few areas in the intercostal and
bdominal musculature being weakly b-gal positive. How-
ever, X-gal staining in muscles derived from the rostral
myotomes appeared to be less affected by the lack of Myf5.
Accordingly, weak lacZ expression was detected in the fore-
but not in the hindlimbs of the Myf5 KO embryos.
E11.5 embryos subjected to X-gal staining were coronally
ectioned at the interlimb level and counterstained with
ematoxylin. Figures 3M and 3N show the restricted ex-
ression of lacZ in the myotomes of Myf52/2 embryos,
which is confined to the ventral myotomes, compared to
the wild type. On the other hand, lacZ expression in the
MyoD2/2 embryos was essentially identical to that of the
wild type (data not shown). Together these results indicate
that Myf5 is required for full expression of the Fgf4 gene in
the myotomes, while MyoD is dispensable. In Myf52/2
embryos a delay in the formation of myotomes until MyoD
is turned on (E10.5–11) has been observed. Thus the absence
of Fgf4 transgene expression in the Myf52/2 embryos could
be due to delay in the formation of the myotomes. How-
ever, the expression of our Fgf4 transgenes is also strongly
inhibited at all subsequent stages of muscle development
(from E10.5 to E13.5) and thus this latter explanation seems
unlikely.
In the Absence of Myf5, MyoD Is Required for
Fgf4-lacZ Expression in the Ventral Myotomes
The in vivo experiments suggest that Myf5 is required for
Fgf4 expression in the myotomes. However, EMSAs of Fig.
2 showed that not only MYF5, but also MYOD, can bind
E-box 2 and thus could also be involved in activating Fgf4
gene expression. Thus, we asked whether the residual
domain of lacZ expression in the ventral myotome of the
Myf5-deficient embryos was MyoD dependent.
Fgf4-lacZ transgenic mice carrying a single copy of each
of the genes MyoD and Myf5 were crossed to produce
transgenic embryos deficient for both MyoD and Myf5 and
analyzed for lacZ expression (Fig. 4). Embryos deficient for
both genes do not develop muscle (Rudnicki et al., 1993)
and did not show any lacZ-positive cells (Fig. 4D, compare
to Figs. 4A and 4B).
We then produced Myf52/2:MyoD1/2 Fgf4-lacZ E11.5
embryos which were stained with X-gal (Fig. 4C) and
subsequently sectioned at the interlimb level. Mice lacking
Myf5 and one copy of MyoD display no obvious morpho-
ogical abnormalities in size and form muscles (Rudnicki et
s of reproduction in any form reserved.
398 Fraidenraich et al.FIG. 3. Fgf4-lacZ expression in the myotomes of Myf5- but not of MyoD-deficient embryos is severely impaired. Wild-type (A, D, G, and
J), Myf5 null (B, E, H, and K), and MyoD null (C, F, I, and L) embryos transgenic for Fgf4-lacZ (see Material and Methods) were harvested
at E10.5–11.0 (A, B, and C), E11.5 (D, E, and F), E12.5 (G, H, and I), and E13.5 (J, K, and L) and subjected to X-gal staining. The two constructs
used to create transgenic mouse lines were described elsewhere (constructs 2 and 5 in Fraidenraich et al., 1998). Construct 2 bears a
fragment of the Fgf4 39 UTR consisting of Hom3a, Hom3b, and 59 and 39 flanking sequences. Construct 5 39 UTR fragment includes Hom2,
intervening sequences, Hom3a, Hom3b carrying a 20-bp deletion corresponding to the SOX/OCT binding sites, and flanking sequences. The
deletion in the SOX/OCT binding sites has been shown not to affect the pattern of expression of the transgene in the myotomes
(Fraidenraich et al., 1998). The ectopic staining in the brain at E10.5–11.0 (A, B, and C) results from a position effect (Fraidenraich et al.,
1998). Residual areas of stain are detected in the Myf5-deficient embryos at E11.5 and E12.5 (arrowheads). (M and N) Wild-type and
Myf52/2 embryos from D and E were sectioned at the interlimb level and counterstained with hematoxylin. d, dorsal; v, ventral; derm,
dermatome; scl, sclerotome; nt, neural tube.
(399Fgf4 Regulation by Myogenic bHLH Factors and ShhFIG. 4. In the absence of Myf5, MyoD is required for Fgf4-lacZ expression in the ventral myotomes. (A through D) Myf51/2:MyoD1/2
A), Myf52/2 (B), Myf52/2:MyoD1/2 (C), and Myf52/2:MyoD2/2 (D) embryos transgenic for Fgf4-lacZ were harvested at E11.5 and
subjected to X-gal staining.
FIG. 5. The myotomes of Myf52/2:MyoD1/2 embryos express desmin. E.11.5 wild-type (A) and Myf52/2:MyoD1/2 (B) Fgf4-lacZ
transgenic embryos X-gal stained were sectioned at the interlimb level and immunostained with anti-MYOD antibodies. E12.5 Myf52/2
(C) and Myf52/2:MyoD1/2 (D) Fgf4-lacZ transgenic embryos X-gal stained were sectioned at the interlimb level and immunostained with
anti-desmin antibodies. d, dorsal; v, ventral; scl, sclerotome; derm, dermatome; nt, neural tube.
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400 Fraidenraich et al.al., 1993). Although one copy of MyoD appears capable of
rescuing skeletal myogenesis in mice lacking Myf5 (Rud-
icki et al., 1993), essentially no lacZ-positive cells were
bserved (Fig. 4C). The sections were immunostained with
nti-MYOD or anti-desmin antibodies (Fig. 5). At E11.5 a
ew MYOD-positive cells were observed that, however, did
ot express lacZ (Fig. 5B). At E12.5 again LacZ staining was
bsent, but expression of desmin, a marker of muscle
ifferentiation, was clearly detectable in the myotomes of
yf52/2:MyoD1/2 embryos (Fig. 5D), in line with the
revious observation (Rudnicki et al., 1993) that these mice
evelop normal muscles. The observation that the residual
ctivity of the FGF4 myotome enhancer observed in Myf5
ull embryos is abolished in a MyoD1/2 background
upports the hypothesis that this residual activity is MYOD
ependent. Furthermore, since MyoD1/2:Myf52/2 em-
ryos form muscles, these results suggest that FGF4 may
ot be critical for skeletal myogenesis.
An Fgf4-CAT Reporter Plasmid under the Control
of E-box 2 but Not of E-box 1 Is Transactivated by
MYF5 and MYOD
In the previous sections we showed that E-box 2 but not
E-box 1 can bind MYF5 and MYOD, is required for trans-
gene expression in the myotomes, and cannot be substi-
tuted by any other E box of the 39 UTR. Furthermore, Myf5
ppeared to be essential for activity of the Fgf4 enhancer in
he myotome, although MyoD could partially compensate
for the absence of Myf5. We therefore performed a series of
transfection experiments to determine whether the intro-
duction of myogenic bHLHs in cell lines devoid of these
factors activated the expression of Fgf4-CAT reporter plas-
mids controlled by E-box 2.
Figure 6A shows the constructs used in these experi-
ments. Construct 3a1 contains the 59 half of Hom3a,
ncluding E-box 1 and E-box 2, while construct 3a2 contains
he 39 half of Hom3a. Construct 8X(E-box 1) or construct
X(E-box 2) is a multimer of a 20-mer DNA unit containing
-box 1 or E-box 2.
We transfected constructs 3a1 and 3a2 in C2-7 myoblasts
nd NIH 3T3 fibroblasts. The basal activities for both
onstructs were similarly low. However, when the cells
ere cotransfected with expression plasmids for Myf5 or
yoD, approximately 10-fold induction of the activity of
a1 and no induction of 3a2 occurred (Figs. 6B and 6C). We
lso performed the same analysis with HeLa cells and
btained similar results (data not shown). We next tested
he constructs 8X(E-box 1) and 8X(E-box 2) in HeLa cells. A
obust transactivation of 8X(E-box 2) but not of 8X(E-box 1)
AT activity occurred when either Myf5 or MyoD expres-
ion plasmid was cotransfected (Fig. 6D).
Taken together these results indicate that the DNA
lements comprising E-box 2 can serve as a target for
ransactivation by MYF5 and MYOD, while the E-box 1
lements do not respond to Myf5 and MyoD expression. In m
Copyright © 2000 by Academic Press. All rightddition, they confirm the hypothesis that the first half of
he Hom3a region is essential for myotome expression.
While MYOD or MYF5 or both are present in proliferat-
ng myoblasts and differentiated myotubes, myogenin and
RF4 are activated upon differentiation. However, the
nhibitory HLH protein Id, which lacks the basic DNA-
inding domain, has been shown to inhibit MYOD/E com-
lexes from binding DNA in proliferating myoblasts
Benezra et al., 1990). Upon differentiation, when Id protein
evels fall, these hetero-oligomeric complexes now bind
ith high affinity to response elements in muscle-specific
enes. We tested the ability of the E-box 2 element to bind
yogenic bHLH-like activities and to activate an Fgf4-CAT
lasmid in C2-7 myoblasts undergoing differentiation. At
ifferent time points during differentiation nuclear extracts
ere prepared and incubated with the E-box 2 probe (Fig.
E). At 90 h after serum starvation cells became positive for
HC. Concomitantly, EMSA analysis showed the appear-
nce of a broad gel-shift band (denoted complex a). Complex
presented a mobility similar to those of MYF5- and
YOD-containing complexes and was competed with
-box 2 but not with CAGGTA. Other bands of faster
obility (complexes b through e) were also detected, but
ppeared to be nonspecific (i.e., were not efficiently com-
eted) or did not vary upon differentiation. We then trans-
ected 8X(E-box 1) or 8X(E-box 2) into myoblasts and al-
owed the cells to differentiate for 90 h. A robust activation
f 8X(E-box 2) but not of 8X(E-box 1) construct was observed
Fig. 6E).
In an attempt to identify some of the components of the
omplexes appearing in the band-shift experiments, we
erformed a supershift experiment with extracts from dif-
erentiating C2-7 cells, probe E-box 2, and the anti-MYOD
b. Only complex a was significantly supershifted and the
upershifted complex presented a mobility similar to that
bserved for MYOD:anti-MYOD Ab control (Fig. 2F). This
ndicates that MYOD is a major component of complex a. A
esidual binding activity, however, was observed in the
aster mobility area of the broad complex a, which was less
ffected by the addition of the anti-MYOD Ab, suggesting
hat nuclear factors other than MYOD may be contained in
omplex a. Interestingly, the MYF5 control band (Fig. 2E,
ane 10) runs slightly faster than the MYOD control band
Fig. 2E, lane 11) and with a mobility similar to that
bserved for the residual binding activity of complex a. All
he other bands observed in the nuclear extracts from C2-7
ells were not supershifted (Fig. 2F).
Taken together these results indicate that in vitro, the
gf4 myotome enhancer can be activated both by MYOD
nd by MYF5 and does not show any preference for MYF5
ver MYOD, contrary to what is observed in vivo. As
iscussed in detail later, we tend to interpret these results
s indicating that both MYOD and MYF5 can equally
ctivate the enhancer, but that in vivo, the pattern and
iming of gene expression of these factors make MYF5 the
ost relevant element.
s of reproduction in any form reserved.
b
o
d
S
m
c
h
I
o
i
M
M
T
). Th
401Fgf4 Regulation by Myogenic bHLH Factors and ShhFgf4-lacZ Is Not Activated in the Myotomes of Shh
Null Embryos
Shh signals from the notochord and the neural plate have
een shown to play a key role in influencing the expression
f myogenic bHLH factors (Munsterberg et al., 1995). While
Shh has an essential inductive function in the early activa-
tion of Myf5 and MyoD in the dorsal myotome, Shh
signaling is not required for expression of Myf5 and MyoD
in the ventral myotome (Borycki et al., 1999).
We tested the activation of the Fgf4-lacZ transgene in the
myotomes of the Shh2/2 embryos. X-gal staining was
FIG. 6. An Fgf4-CAT plasmid under the control of E-box 2 but
representation of the constructs used to transfect various cell line
8X(E-box-2) contains eight repeats of a 20-bp unit encompassing E
Construct 3a1 or 3a2 was transfected in C2-7 myoblasts. (B) or NIH
expression plasmids as indicated below the histograms. (D) Cons
presence or absence of CMV-Myf5 or CMV-MyoD expression plasm
transfected reporter construct alone was given the value of 1 in B, C
allowed to proliferate (10% CS) or induced to differentiate (1% HSundetectable or extremely weak in the myotomes and m
Copyright © 2000 by Academic Press. All righterivative muscles of E10.5, E11.5, E12.5, and E13.5.
hh2/2 embryos, including both dorsal and ventral do-
ains (Figs. 7A and 7B and data not shown). In only a few
ases could we detect very weak b-gal expression in the
ypaxial myotomes, but not in epaxial myotomes (Fig. 7B).
mmunohistochemistry performed on transverse sections
f E11.5 Shh2/2 Fgf4-lacZ transgenic embryos at the
nterlimb or tail level revealed remarkable features. Anti-
YOD or anti-myogenin antibodies did not detect any
YOD- or myogenin-positive cells in the dorsal domain.
he ventral domain was, however, positive for MYOD and
f E-box 1 is transactivated by MYF5 and MYOD. (A) Schematic
1 contains E-boxes 1 and 2. 3a2 contains no E box. 8X(E-box 1) or
1 or E-box 2. For coordinates see Material and Methods. (B and C)
cells (C) in the presence or absence of CMV-Myf5 or CMV-MyoD
8X(E-box1) or 8X(E-box 2) was transfected in HeLa cells in the
as indicated below the histogram. CAT activity generated by each
d D. (E) C2-7 cells transfected with 8X(E-box1) or 8X(E-box 2) were
e values represent the averages of at least three experiments.not o
s. 3a
-box
3T3
truct
ids
, anyogenin and was considerably expanded toward the scle-
s of reproduction in any form reserved.
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402 Fraidenraich et al.rotome (Figs. 7C–7E), particularly at the tail level. The
absence of Shh allowed MYOD-positive cells to occupy
adjacent ventral regions in close proximity to the notochord
and the neural plate. MYOD-positive cells from both left
and right myotomes joined at the midline in the proximity
of the notochord and no discernible separation between the
FIG. 7. Fgf4-lacZ expression is severely impaired in the myo-
omes of the Shh null embryos. (A and B) Shh2/2:Fgf4-lacZ
ransgenic embryos were harvested at E10.5 (A) or E11.5 (B) and
-gal stained. (C–E) An E11.5 Shh2/2:Fgf4-lacZ embryo was X-gal
tained, sectioned at interlimb (C, E) and tail (D) levels, and
mmunostained with anti-MYOD (C, D) or anti-myogenin (E)
ntibodies. (F–I) Wild-type (F and G) and Shh2/2 (H and I) trans-
enic embryos for Fgf4-lacZ were harvested at E13.5, X-gal stained,
ectioned at the interlimb level, and immunostained with anti-
HC antibodies. d, dorsal; v, ventral; r, rostral; c, caudal; m,
idline; nt, neural tube; vt, vertebrate.two myotomes was observed (Fig. 7D). No lacZ-positive s
Copyright © 2000 by Academic Press. All rightells were observed. These observations indicate that the
resence of myogenic bHLH factors in the ventral myotome
f the Shh null embryos is insufficient for Fgf4 gene
xpression in the myotomes and suggest that Fgf4 expres-
ion is also dependent on Shh signaling.
Immunohistochemistry performed on transverse sections
f E13.5 Shh2/2 embryos Fgf4-lacZ transgenics using anti-
MHC Ab revealed a complete absence of the dorsal muscu-
lature and of a lacZ-positive domain (Figs. 7H and 7I,
compare to a section of a wild-type embryo in Figs. 7F and
7G). In the hypaxial musculature a wall of ectopic MHC-
positive cells continues without interruption through the
midline (Fig. 7I, compare to Fig. 7G), and this could be a
consequence of the expansion of the ventral domain ob-
served at E11.5 (Fig. 7C).
It has been proposed (Laufer et al., 1994; Niswander et al.,
1994) that Fgf4 expression in the limb-bud AER requires
Shh signaling originating from the zone of polarizing activ-
ity (ZPA). Surprisingly, however, the limb-bud AERs of
E10.5 and E11.5 Shh null embryos were clearly lacZ posi-
tive (Fig. 7A and data not shown).
DISCUSSION
The experiments presented in this report were aimed at
identifying the mechanisms underlying the expression of
Fgf4 in the somitic myotomes of the developing embryo.
We showed earlier that the Fgf4 gene contains cassette-like
DNA elements, located in the 39 UTR of the gene, that
direct gene expression to specific developmental stages and
structures. The best characterized of these elements is the
Fgf4 EC cell enhancer, which corresponds to the Hom3b
conserved region of the Fgf4 39 UTR and is responsible for
Fgf4 expression in the ICM of the blastocyst as well as in EC
and ES cells. This enhancer is synergistically activated by
two transcriptional regulators, SOX2 and OCT-3, that bind
to adjacent sites on the Fgf4 enhancer DNA (Curatola and
Basilico, 1990; Dailey et al., 1994; Yuan et al., 1995;
Fraidenraich et al., 1998).
Previous results, obtained through a transgenic analysis
f the Fgf4 elements required to drive b-gal expression in
specific structures of the developing mouse embryo, had
indicated that another conserved Fgf4 DNA fragment
ermed Hom3a, also located in the 39 UTR of the gene,
ontained cis elements necessary and sufficient for both
yotome and AER expression. The myotomes and AER
NA elements overlapped, but appeared to be distinct since
utations of the two E boxes contained in Hom3a abol-
shed myotome, but not AER, expression (Fraidenraich et
l., 1998). Here we show that only the second of these two
boxes is essential for the activity of the Fgf4 myotome
nhancer and that the myogenic factor MYF5 plays a major
ole in the activation of this element. MYOD, which can
lso bind and stimulate this element in vitro, can only
artially compensate for the absence of MYF5. We also
how that Shh is required for Fgf4 expression in the myo-
s of reproduction in any form reserved.
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403Fgf4 Regulation by Myogenic bHLH Factors and Shhtomes and that the role of Shh may not result solely from its
bility to activate the myogenic factors, suggesting that
ther transcriptional regulatory factors are involved.
A Conserved E box Located in the Hom3a Region
Controls Fgf4 Expression in the Myotomes
As alluded to above, the myotome enhancer element we
have identified contains two E boxes, which are known
binding sites for the family of bHLH transcription factors,
including the myogenic factors MYOD and MYF5. The
sequences of these two E boxes differ in the two central
nucleotides (CACATG, box 1; CAGCTG, box 2), which are
known to influence the specificity of binding of bHLH
factors. By analyzing transgenic embryos in which lacZ
expression was controlled by the Hom3a Fgf4 region, we
found that only E-box 2 was essential, while E-box 1
appeared to play no role. Accordingly, we found that DNA
probes corresponding to E-box 2 and flanking sequences
bound MYOD and MYF5 in gel-shift assays, while E-box 1
did not show appreciable activity. Furthermore, another
lacZ construct containing a mutated E-box 2 within most of
he 39 UTR sequences failed to activate b-gal expression in
he myotomes. This transgene contains six intact E boxes
n addition to the mutated E box. This strongly suggests
hat E-box 2 cannot be substituted by any other E box
resent in the 39 UTR. It is worth mentioning that none of
he additional E boxes has the exact sequence (CAGCTG) of
-box 2. The requirement for E-box 2 appeared to be specific
or expression in the myotomes but not for the limb-bud
ER where lacZ expression was not perturbed by mutating
-box 2.
It is interesting to note that the Hom3a element is overall
ighly conserved in the human, mouse (Curatola and Ba-
ilico, 1990), chicken (unpublished), and zebrafish (B.
raper, in preparation) Fgf4 genes, but only E-box 2 is
erfectly conserved in these four species. Previous studies
n regulation of expression of myogenic factors through
-box elements showed that mutation of one E box in the
yogenin promoter in the context of a minimal sequence
133 bp) abrogated lacZ expression in the myotomes (Yee
nd Rigby, 1993). However, when this mutation was ana-
yzed in the context of longer fragments containing other E
oxes, no abrogation was observed (Yee and Rigby, 1993;
heng et al., 1993). A core motif in the MyoD distal
nhancer contains four E boxes. However, mutations of
hese E boxes did not alter the pattern of lacZ transgene
xpression in the myotomes (Goldhamer et al., 1995).
ecent studies performed on the MyoD core enhancer
dentified a 30-bp segment which responds to Myf5. Inter-
estingly, an E box with the sequence CAGCTGTT lies in
the center of this element (Kucharczuk et al., 1999). The
sequence CTGTC/T—present also in E-box 2—has been
also shown to act as a preferred half site for MYOD binding
(Blackwell and Weintraub, 1990).
Copyright © 2000 by Academic Press. All rightMyf5 Appears to Be the Main Myogenic Factor
Involved in Fgf4 Expression in the Myotomes
The results described above prompted us to examine the
role of Myf5 and MyoD on Fgf4 gene expression in the
yotomes. Myf5 is the first of the myogenic bHLH genes to
e expressed during mouse embryogenesis, with transcripts
bserved initially in the dermamyotome and later in the
yotome between E8.0 and E14.5 (Ott et al., 1991), while
MyoD is expressed in the myotome beginning at E10 and
throughout development and adulthood (Sassoon et al.,
1989). Myf5-null mice do not form the distal part of the ribs
but exhibit normal skeletal muscle development at birth
because of the expression of MyoD (Rudnicki et al., 1993).
hey show, however, a delay in myotome maturation and it
as been suggested that this delay of early myotome matu-
ation is responsible for the rib cage defect (Braun et al.,
992). More recent studies have led to the suggestion that in
he Myf5 KO embryos there is a delay in the development of
he epaxial (paraspinal and intercostal) musculature, but
he hypaxial (limbs and abdominal wall) musculature de-
elops on schedule (Kablar et al., 1997). Previous studies
ave described that the expression of members of the FGF
amily was absent or delayed in the somites (E9.5–10.5) of
yf5 null embryos (Grass et al., 1996), but did not investi-
ate their expression in the myotomes at later stages.
By crossing our transgenic lines with Myf5 or MyoD
nockout mice we have observed that lacZ expression was
nchanged in the myotomes of MyoD2/2 embryos, but
as almost completely suppressed in a Myf52/2 back-
round. However, some residual X-gal staining was ob-
erved in the ventral portion of Myf5 null myotomes. By
xamining Myf52/2:MyoD1/2 or MyoD2/2 embryos we
ould show that the residual transgene expression in the
bsence of Myf5 requires the expression of MyoD. Thus,
yoD could compensate, at least partially, for the absence
f Myf5 in the ventral myotomes.
These observations have to be interpreted also in the
context of our in vitro experiments, which show that both
MYF5 and MYOD bind equally to the E-box 2 sequence in
the Fgf4 myotome enhancer and can stimulate gene expres-
sion from a CAT reporter plasmid under the control of
myotome enhancer sequences. We believe that the best
interpretation of these data is that MYF5 is the main
myogenic factor required to drive Fgf4 gene expression in
the myotomes and that it can be replaced by MYOD in the
ventral myotomes, but that this requirement does not
reflect an intrinsic ability of MYF5 and not MYOD to
activate the myotome enhancer. Rather we believe that in
principle both MYF5 and MYOD can transactivate the Fgf4
myotome enhancer, but that in vivo only Myf5 is expressed
in the specific temporal and spatial pattern required for Fgf4
enhancer activation. This hypothesis finds support in a
recent finding obtained by P. Soriano (manuscript in prepa-
ration). Knock-in mice in which the Myf5 gene is replaced
by MyoD and in which therefore MyoD is expressed under
the regulatory elements of Myf5 do not display the rib
s of reproduction in any form reserved.
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404 Fraidenraich et al.defects of Myf5 KO mice. Thus in this case, MyoD can
substitute for Myf5 function.
It is likely that another transcription factor(s) must coop-
erate with MYF5 to promote Fgf4 expression in the myo-
tomes. The hypothesis is not only supported by the general
consensus that specific regulation of gene expression during
development results from the combinatorial action of mul-
tiple transcription factors, but also from the following
observations: (i) Both Myf5 and MyoD expressions in the
myotomes of E11.5 embryos are much more widespread
than that of Fgf4, which is restricted to a central portion of
the myotomes; (ii) many tissues and cell lines (e.g., differ-
entiated myoblasts) express MyoD and Myf5 but not Fgf4;
and (iii) our preliminary results indicate that transgenic
constructs containing only the 59 160 nucleotides of the
Hom3a region (i.e., the myotomal enhancer), which include
E-box 2, are not capable of driving lacZ expression in the
myotomes, indicating that other DNA elements located in
the 39 half of the myotome enhancer are required. In this
view, Myf5 could be expressed in cells of the epaxial lineage
which coexpress another factor instrumental for Fgf4 acti-
vation, and MyoD could be mostly expressed in cells of the
hypaxial lineage, which lack the hypothetical coactivator.
The 39 half of Hom3a contains several AT-rich regions,
including a consensus for myocyte enhancer factor 2
(MEF2) binding site—YTA(A/T)4TAR (Black and Olson,
998). The combinatorial action of proteins from the myo-
enic bHLH and the MEF2 families appears to represent a
ranscriptional code specific for skeletal muscle gene acti-
ation. However, expression of Mef2 is broadly detected in
myogenic and nonmyogenic lineages during mouse em-
bryogenesis (Black and Olson, 1998) and thus may not
explain the restricted pattern of expression of Fgf4.
Shh Is Required for Fgf4 Gene Expression in the
Myotomes
The establishment of the myogenic program is specified
by a precise number of instructions emanated from sur-
rounding tissues. Thus for example, Shh signals from the
notochord and floor plate, in combination with Wnt family
members which are expressed in dorsal regions of the
neural tube, induce myogenic bHLH gene expression in the
somite (Munsterberg et al., 1995). Another key regulator of
somitic myogenesis is the transcription factor PAX3. Wnt
and Shh signals can induce somitic expression of Pax3
oncomitantly with the expression of Myf5 and prior to
yoD. Indeed, infection of embryonic tissues in vitro with
retrovirus encoding PAX3 is sufficient to induce expres-
ion of MyoD, Myf5, and myogenin in paraxial and lateral
late mesoderm in the absence of inducing tissues (Maroto
t al., 1997). Furthermore, Pax3 (Splotch):Myf5 double-
utant embryos were found to be devoid of MyoD, suggest-
ng that MyoD acts genetically downstream of these genes
or myogenesis (Tajbakhsh et al., 1997). Targeted gene
isruption of Shh showed defects in tissues that are beyond
he normal sites of Shh transcription, confirming the pro-
Copyright © 2000 by Academic Press. All rightosed role of SHH as an extracellular signal required for the
issue-organizing properties of several vertebrate patterning
enters (Chiang et al., 1996). In particular during myogen-
sis, Shh has an essential inductive function in the activa-
ion of Myf5 and MyoD in the epaxial somite cells but is not
equired for the expression of Myf5, MyoD, and Pax3 in the
ypaxial dermamyotomal cells (Borycki et al., 1999). We
nalyzed the pattern of expression of Fgf4-lacZ in the
yotomes of Shh mutant embryos and found no detectable
xpression. While the absence of b-gal expression in the
presumptive dorsal myotome was expected, since no myo-
genic factors are present, the fact that Fgf4 is not activated
in the ventral myotomes suggests that Fgf4 expression in
the myotomes is dependent on Shh signaling and that the
myogenic bHLH factors are not sufficient for Fgf4 expres-
sion in the absence of Shh. We interpret this finding as
indicating that Shh induces the expression of other tran-
scription factors which cooperate with MYF5 in the activa-
tion of the Fgf4 myotome enhancer and that, in their
absence, no Fgf4 expression is detected. Since PAX3 is
expressed in the hypaxial myotomes of Shh2/2 embryos
(Borycki et al., 1999), however, PAX3 is unlikely to be such
a factor. We cannot, however, exclude the possibility that in
the absence of Shh, the integrity of the hypaxial myotome is
compromised and the expression levels of the myogenic
factors are reduced. This hypothesis is supported by the
observation that the ventral somites of Shh null embryos
undergo considerable apoptosis (Borycki et al., 1999; our
unpublished observations) that could lead to extremely
reduced levels of bHLH factors. We are currently undertak-
ing mutational analysis of the Fgf4 myotome enhancer to
identify MYF5 coactivators and to address if they are Shh
dependent.
It has been proposed that Fgf4 expression in the limb-bud
AER requires Shh signaling from the limb mesenchyme
ZPA and that Shh and Fgf4 were under a complex form of
reciprocal regulation (Niswander et al., 1994; Laufer et al.,
1994). However, we found that Fgf4-lacZ was expressed in
the limb-bud AER of Shh null embryos at E10.5–E11.5. This
is in agreement with recent findings showing that expres-
sion of the BMP antagonist gremlin is sufficient to induce
Fgf4 in the AER and establish the SHH/FGF4 feedback loop,
although only until E10.25 and in a restricted portion of the
AER (Zuniga et al., 1999). FGF4 activation was independent
of Shh signaling. BMPs and FGFs may antagonize one
another during limb-bud development (Niswander and Mar-
tin, 1993). Therefore, inhibition of BMP activity in the
limb-bud compartments by BMP antagonists might over-
ride BMP-mediated Fgf4 repression (Pizette and Niswander,
1999). We have identified a cis-acting negative regulatory
element controlling Fgf4 expression in the AER (Fraiden-
raich et al., 1998) and this element could be a target of
transcriptional repression by Bmp signaling.
As in the case of the AER, somitic myogenesis is also
under negative regulation (Reshef et al., 1998). Bmp signal-
ing serves to inhibit the activation of MyoD and Myf5 in
Pax3-expressing cells, and the BMP antagonist noggin,
s of reproduction in any form reserved.
p
a
b
a
e
a
t
F
t
w
W
s
v
n
F
F
m
t
r
s
t
p
i
m
M
t
w
c
t
405Fgf4 Regulation by Myogenic bHLH Factors and Shhectopically expressed lateral to the somite, expands MyoD
expression and induces formation of a lateral myotome
(Reshef et al., 1998). The somites of noggin null embryos
show a severe reduction of MyoD expression (McMahon et
al., 1998). The fact that Fgf4 is not expressed in the dorsal
nor in the ventral myotomes of Shh null embryos, however,
suggests that Fgf4 cannot be initially activated through a
Shh-independent mechanism. Thus it is unlikely that Fgf4
expression in the myotomes is initiated by antagonists of
BMP as has been proposed for Fgf4 expression in the
limb-bud AER.
Developmental Role of Fgf4 Expression in the
Myotomes
Although our experiments were focused on the identifi-
cation of the mechanisms regulating Fgf4 expression during
embryogenesis, and not directly aimed at understanding the
role of Fgf4 signaling in development, some of the data
resented here have a bearing on this subject. Several Fgfs
re expressed in the myotomes, most notably Fgf4, 5, and 6,
ut the phenotypes of Fgf5 and Fgf6 KO mice do not suggest
specific, unique role in muscle development, while the
arly lethality of Fgf4 null embryos has precluded the
ssessment of its role in the myotomes (Herber et al., 1994;
Floss et al., 1997; Feldman et al., 1995). Our data suggest
hat FGF4 is not essential for skeletal myogenesis. (I)
gf4-lacZ gene expression is greatly reduced and restricted
o the ventral portion of the myotomes in Myf5 null mice,
hich, however, form a normal skeletal musculature. (II)
e have observed a total absence of Fgf4 transgene expres-
ion in Myf5 null, MyoD1/2 mice, which although not
iable, can develop skeletal muscles. Thus either Fgf sig-
aling is not essential for muscle development or the role of
GF4 in this process is redundant with that of FGF5 or
GF6. The creation of compound null mice, and experi-
ents aimed at specifically abolishing Fgf4 expression in
he myotome, which are currently in progress in our labo-
atory, should eventually answer these questions.
In conclusion, the experiments presented in this report
how that Fgf4 expression in the myotomes, studied
hrough a sensitive system of transgenic expression, de-
ends on a specific and conserved enhancer element located
n the 39 UTR and that this element must interact with the
yogenic factor MYF5 to direct sustained Fgf4 expression.
yoD can partially compensate for the absence of Myf5 in
he hypaxial lineage. Furthermore, other factors, some of
hich are likely to be controlled by Shh signaling, must
ooperate with MYF5 in promoting expression of Fgf4 in
he myotomes.
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